Evaluation of fluorescein diacetate for flow cytometric determination of cell viability in orthopaedic research

R. S. Bell, L. A. Bourret, D. F. Bell, M. C. Gebhardt, Andrew Rosenberg, H. B. Berrey, B. V. Treadwell, W. W. Tomford, H. J. Mankin

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Accurate estimation of cellular viability is important both in research and in aspects of orthopaedic clinical practice. We have been interested in the potential for flow cytometric application of fluorescein diacetate (FDA) in evaluating chondrocyte survival following cryopreservation of osteochondral allografts as well as in the assessment of sarcoma necrosis following preoperative chemotherapy. In order to evaluate the suitability of this method for cell viability assays, this study compared FDA with more traditional methodology (trypan blue, clonigenic assay, metabolic activity analysis, measurement of DNA synthesis, and histological assessment of necrosis). Both chondrocytes and sarcoma cells were exposed to various experimental injuries prior to viability analysis. Although it is evident from these experiments that FDA accurately reflects cell survival after physical injury, it underestimates the effect of chemotherapy on cell reproductive potential in vitro. However, FDA is highly correlated with histological assessment of tumor viability after chemotherapy in vivo. It is apparent that the methodology chosen for determination of viability should be appropriate for the type of experimental injury and should analyze the cell function (i.e., metabolic activity or reproductive capacity) that is appropriate for the experimental model.

Original languageEnglish
Pages (from-to)467-474
Number of pages8
JournalJournal of Orthopaedic Research
Volume6
Issue number4
StatePublished - Jul 1 1988
Externally publishedYes

Fingerprint

Orthopedics
Cell Survival
Chondrocytes
Research
Drug Therapy
Sarcoma
Wounds and Injuries
Necrosis
Trypan Blue
Cryopreservation
Allografts
Theoretical Models
3',6'-diacetylfluorescein
DNA
Neoplasms

ASJC Scopus subject areas

  • Orthopedics and Sports Medicine

Cite this

Bell, R. S., Bourret, L. A., Bell, D. F., Gebhardt, M. C., Rosenberg, A., Berrey, H. B., ... Mankin, H. J. (1988). Evaluation of fluorescein diacetate for flow cytometric determination of cell viability in orthopaedic research. Journal of Orthopaedic Research, 6(4), 467-474.

Evaluation of fluorescein diacetate for flow cytometric determination of cell viability in orthopaedic research. / Bell, R. S.; Bourret, L. A.; Bell, D. F.; Gebhardt, M. C.; Rosenberg, Andrew; Berrey, H. B.; Treadwell, B. V.; Tomford, W. W.; Mankin, H. J.

In: Journal of Orthopaedic Research, Vol. 6, No. 4, 01.07.1988, p. 467-474.

Research output: Contribution to journalArticle

Bell, RS, Bourret, LA, Bell, DF, Gebhardt, MC, Rosenberg, A, Berrey, HB, Treadwell, BV, Tomford, WW & Mankin, HJ 1988, 'Evaluation of fluorescein diacetate for flow cytometric determination of cell viability in orthopaedic research', Journal of Orthopaedic Research, vol. 6, no. 4, pp. 467-474.
Bell, R. S. ; Bourret, L. A. ; Bell, D. F. ; Gebhardt, M. C. ; Rosenberg, Andrew ; Berrey, H. B. ; Treadwell, B. V. ; Tomford, W. W. ; Mankin, H. J. / Evaluation of fluorescein diacetate for flow cytometric determination of cell viability in orthopaedic research. In: Journal of Orthopaedic Research. 1988 ; Vol. 6, No. 4. pp. 467-474.
@article{fe632e92f89d451fa959348adafd2f3f,
title = "Evaluation of fluorescein diacetate for flow cytometric determination of cell viability in orthopaedic research",
abstract = "Accurate estimation of cellular viability is important both in research and in aspects of orthopaedic clinical practice. We have been interested in the potential for flow cytometric application of fluorescein diacetate (FDA) in evaluating chondrocyte survival following cryopreservation of osteochondral allografts as well as in the assessment of sarcoma necrosis following preoperative chemotherapy. In order to evaluate the suitability of this method for cell viability assays, this study compared FDA with more traditional methodology (trypan blue, clonigenic assay, metabolic activity analysis, measurement of DNA synthesis, and histological assessment of necrosis). Both chondrocytes and sarcoma cells were exposed to various experimental injuries prior to viability analysis. Although it is evident from these experiments that FDA accurately reflects cell survival after physical injury, it underestimates the effect of chemotherapy on cell reproductive potential in vitro. However, FDA is highly correlated with histological assessment of tumor viability after chemotherapy in vivo. It is apparent that the methodology chosen for determination of viability should be appropriate for the type of experimental injury and should analyze the cell function (i.e., metabolic activity or reproductive capacity) that is appropriate for the experimental model.",
author = "Bell, {R. S.} and Bourret, {L. A.} and Bell, {D. F.} and Gebhardt, {M. C.} and Andrew Rosenberg and Berrey, {H. B.} and Treadwell, {B. V.} and Tomford, {W. W.} and Mankin, {H. J.}",
year = "1988",
month = "7",
day = "1",
language = "English",
volume = "6",
pages = "467--474",
journal = "Journal of Orthopaedic Research",
issn = "0736-0266",
publisher = "John Wiley and Sons Inc.",
number = "4",

}

TY - JOUR

T1 - Evaluation of fluorescein diacetate for flow cytometric determination of cell viability in orthopaedic research

AU - Bell, R. S.

AU - Bourret, L. A.

AU - Bell, D. F.

AU - Gebhardt, M. C.

AU - Rosenberg, Andrew

AU - Berrey, H. B.

AU - Treadwell, B. V.

AU - Tomford, W. W.

AU - Mankin, H. J.

PY - 1988/7/1

Y1 - 1988/7/1

N2 - Accurate estimation of cellular viability is important both in research and in aspects of orthopaedic clinical practice. We have been interested in the potential for flow cytometric application of fluorescein diacetate (FDA) in evaluating chondrocyte survival following cryopreservation of osteochondral allografts as well as in the assessment of sarcoma necrosis following preoperative chemotherapy. In order to evaluate the suitability of this method for cell viability assays, this study compared FDA with more traditional methodology (trypan blue, clonigenic assay, metabolic activity analysis, measurement of DNA synthesis, and histological assessment of necrosis). Both chondrocytes and sarcoma cells were exposed to various experimental injuries prior to viability analysis. Although it is evident from these experiments that FDA accurately reflects cell survival after physical injury, it underestimates the effect of chemotherapy on cell reproductive potential in vitro. However, FDA is highly correlated with histological assessment of tumor viability after chemotherapy in vivo. It is apparent that the methodology chosen for determination of viability should be appropriate for the type of experimental injury and should analyze the cell function (i.e., metabolic activity or reproductive capacity) that is appropriate for the experimental model.

AB - Accurate estimation of cellular viability is important both in research and in aspects of orthopaedic clinical practice. We have been interested in the potential for flow cytometric application of fluorescein diacetate (FDA) in evaluating chondrocyte survival following cryopreservation of osteochondral allografts as well as in the assessment of sarcoma necrosis following preoperative chemotherapy. In order to evaluate the suitability of this method for cell viability assays, this study compared FDA with more traditional methodology (trypan blue, clonigenic assay, metabolic activity analysis, measurement of DNA synthesis, and histological assessment of necrosis). Both chondrocytes and sarcoma cells were exposed to various experimental injuries prior to viability analysis. Although it is evident from these experiments that FDA accurately reflects cell survival after physical injury, it underestimates the effect of chemotherapy on cell reproductive potential in vitro. However, FDA is highly correlated with histological assessment of tumor viability after chemotherapy in vivo. It is apparent that the methodology chosen for determination of viability should be appropriate for the type of experimental injury and should analyze the cell function (i.e., metabolic activity or reproductive capacity) that is appropriate for the experimental model.

UR - http://www.scopus.com/inward/record.url?scp=0024053919&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024053919&partnerID=8YFLogxK

M3 - Article

C2 - 3164067

AN - SCOPUS:0024053919

VL - 6

SP - 467

EP - 474

JO - Journal of Orthopaedic Research

JF - Journal of Orthopaedic Research

SN - 0736-0266

IS - 4

ER -